- Home
- LXEO vs MGTX Comparison
LXEO vs MGTX Comparison
Compare LXEO & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LXEO | MGTX |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 663.5M | 744.9M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | LXEO | MGTX |
|---|---|---|
| Price | $9.38 | $8.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 6 |
| Target Price | $18.22 | ★ $23.83 |
| AVG Volume (30 Days) | ★ 1.2M | 725.9K |
| Earning Date | 11-05-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $27,417,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $619.95 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 96.83 |
| 52 Week Low | $1.45 | $4.55 |
| 52 Week High | $10.38 | $9.73 |
Technical Indicators
Market Signals| Indicator | LXEO | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 53.99 | 58.76 |
| Support Level | $9.27 | $7.60 |
| Resistance Level | $10.04 | $8.34 |
| Average True Range (ATR) | 0.63 | 0.49 |
| MACD | -0.08 | 0.09 |
| Stochastic Oscillator | 59.94 | 97.54 |
Price Performance
Historical ComparisonAbout LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.